Daniel Von Hoff

Daniel Von Hoff

UNVERIFIED PROFILE

Are you Daniel Von Hoff?   Register this Author

Register author
Daniel Von Hoff

Daniel Von Hoff

Publications by authors named "Daniel Von Hoff"

Are you Daniel Von Hoff?   Register this Author

100Publications

5886Reads

32Profile Views

Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer.

J Am Coll Surg 2020 Feb 4. Epub 2020 Feb 4.

Department of Surgery, City of Hope National Medical Center, Duarte, CA; Cancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National, Medical Cancer, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamcollsurg.2019.12.027DOI Listing
February 2020

Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].

Cell Signal 2020 Jan 3;68:109525. Epub 2020 Jan 3.

Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX 77030, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2020.109525DOI Listing
January 2020

Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.

J Cell Physiol 2020 Jan 8. Epub 2020 Jan 8.

Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.29443DOI Listing
January 2020

GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.

J Cell Physiol 2020 Jan 17. Epub 2020 Jan 17.

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.29464DOI Listing
January 2020

Single-Cell Sequencing in Precision Medicine.

Cancer Treat Res 2019 ;178:237-252

Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-16391-4_9DOI Listing
June 2019

Triptolide and Its Derivatives as Cancer Therapies.

Trends Pharmacol Sci 2019 05 8;40(5):327-341. Epub 2019 Apr 8.

Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01656147193004
Publisher Site
http://dx.doi.org/10.1016/j.tips.2019.03.002DOI Listing
May 2019

A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma.

Cell 2019 04 4;177(3):572-586.e22. Epub 2019 Apr 4.

Department of Pharmacology, University of California, San Diego School of Medicine, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA; Moores Cancer Center, University of California, San Diego School of Medicine, La Jolla, CA, USA; Department of Medicine, University of California, San Diego School of Medicine, La Jolla, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00928674193027
Publisher Site
http://dx.doi.org/10.1016/j.cell.2019.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711371PMC
April 2019

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.

Eur J Cancer 2019 Feb 14;108:78-87. Epub 2019 Jan 14.

National Health Research Institutes - National Institute of Cancer Research, No. 367, Sheng-Li Road, Tainan, 70456, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.007DOI Listing
February 2019

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.

Eur J Cancer 2019 Jan 17;106:24-33. Epub 2018 Nov 17.

Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany; German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.09.029DOI Listing
January 2019

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.

Clin Cancer Res 2018 01 1;24(2):266-275. Epub 2017 Aug 1.

Virginia G. Piper Cancer Center Clinical Trials, HonorHealth Research Institute, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1117DOI Listing
January 2018

Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.

World J Gastroenterol 2017 Dec;23(45):7945-7951

Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v23.i45.7945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725289PMC
December 2017

Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer.

PLoS One 2017 25;12(8):e0183871. Epub 2017 Aug 25.

Molecular Medicine Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183871PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571985PMC
October 2017

Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells.

PLoS One 2016 28;11(10):e0165586. Epub 2016 Oct 28.

Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, Arizona, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0165586PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085053PMC
June 2017

Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".

Clin Cancer Res 2017 Apr;23(7):1629-1637

HonorHealth, Scottsdale, Arizona and TGen, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2070DOI Listing
April 2017

Microbiome and pancreatic cancer: A comprehensive topic review of literature.

World J Gastroenterol 2017 Mar;23(10):1899-1908

Natalie Ertz-Archambault, Department of Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Arizona, Scottsdale, AZ 85259, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v23.i10.1899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352932PMC
March 2017

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma.

Anticancer Drugs 2017 02;28(2):127-132

aVirginia G Piper Cancer Center Clinical Trials, HonorHealth Research Institute bDepartment of Internal Medicine, Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale cClinical Translational Research Division, Translational Genomics Research Institute (TGen), Phoenix dDepartment of Internal Medicine, Division of Hematology Oncology, University of Arizona Cancer Center eDepartment of Internal Medicine, University of Arizona, Tucson, Arizona fDepartment of Molecular Medicine, Centre for Individualized Medicine, Rochester, Minnesota, USA gDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000437DOI Listing
February 2017

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.

Pancreas 2017 02;46(2):203-208

From the *Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany; †Mayo Clinic, Scottsdale, AZ; ‡Prince of Wales Hospital, Sydney, New South Wales, Australia; §Celgene Corporation, Summit, NJ; and ∥Translational German Research Institute and Honor Health Research Institute, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000000742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266413PMC
February 2017

Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations.

J Clin Oncol 2017 02 5;35(6):689-690. Epub 2016 Dec 5.

Andrea Wang-Gillam, Washington University School of Medicine, St. Louis, MO; Daniel Von Hoff, TGen, Phoenix; and HonorHealth, Scottsdale, AZ; Jens Siveke, Klinikum rechts der Isar der T U München, Germany; Richard Hubner, The Christie NHS Foundation Trust, Manchester, United Kingdom; Bruce Belanger and J. Marc Pipas, Merrimack Pharmaceuticals, Cambridge, MA; and Li-Tzong Chen, National Health Research Institutes, Tainan, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.1607DOI Listing
February 2017

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

BMC Cancer 2017 02 15;17(1):137. Epub 2017 Feb 15.

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro, Calle Oña, 10, 28050, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3131-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312529PMC
February 2017

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.

Oncology 2016 7;91(5):251-260. Epub 2016 Sep 7.

START Madrid, Centro Integral Oncológico Clara Campal, Madrid Norte Sanchinarro University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448621DOI Listing
January 2017

Human pancreatic cancer progression: an anarchy among CCN-siblings.

J Cell Commun Signal 2016 Sep 19;10(3):207-216. Epub 2016 Aug 19.

Cancer Research Unit, VA Medical Center, Kansas City, 4801 Linwood Blvd, Kansas City, MO, 64128, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12079-016-0343-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055500PMC
September 2016

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

J Gastrointest Oncol 2016 Jun;7(3):469-78

1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2016.01.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880765PMC
June 2016

Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.

Cancer J 2015 Jul-Aug;21(4):299-306

From the Clinical Translational Research Division, The Translational Genomics Research Institute (TGen), Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817719PMC
May 2016

Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.

Lancet 2016 May;387(10032):1997

Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)30365-8DOI Listing
May 2016

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Lancet 2016 Feb 29;387(10018):545-557. Epub 2015 Nov 29.

National Institute of Cancer Research, National Health Research Institutes, Tainan, and Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S014067361500986
Publisher Site
http://dx.doi.org/10.1016/S0140-6736(15)00986-1DOI Listing
February 2016

Hedgehog Pathway Inhibition.

Cell 2016 Feb;164(5):831

Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.02.021DOI Listing
February 2016

Response.

J Natl Cancer Inst 2015 Sep 6;107(9). Epub 2015 Aug 6.

: Department of Medical Oncology, Prince of Wales Hospital, NSW, Australia (DG);HonorHealth and The Translational Genomics Research Institute (TGen), Scottsdale, AZ (DVH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836812PMC
September 2015

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

World J Gastrointest Oncol 2015 Sep;7(9):132-40

Erkut Borazanci, Daniel D Von Hoff, HonorHealth Research Institute, Virginia G. Piper Cancer Center, Scottsdale, AZ 85258, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4251/wjgo.v7.i9.132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569590PMC
September 2015

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.

Clin Cancer Res 2015 Aug 18;21(15):3561-8. Epub 2015 Feb 18.

Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526394PMC
August 2015

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

Oncotarget 2015 Aug;6(23):19819-25

Department of Child Health, University of Arizona College of Medicine, Phoenix, Ronald Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital, Phoenix, Arizona, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637323PMC
http://dx.doi.org/10.18632/oncotarget.4378DOI Listing
August 2015

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411366DOI Listing
July 2015

Use of mechanistic models to integrate and analyze multiple proteomic datasets.

Biophys J 2015 Apr;108(7):1819-1829

Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, Arizona; Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpj.2015.02.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390817PMC
April 2015

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Oncologist 2015 Feb 12;20(2):143-50. Epub 2015 Jan 12.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Division of Oncology, University of Washington, Seattle, Washington, USA; Department of Oncology/Hematology, Sarah Cannon Research Institute, Nashville, Tennessee, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Oncology, Peninsula Oncology Centre, Monash University, Frankston, Victoria, Australia; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA; Division of Clinical Oncology, Medizinische Universität Wien, Vienna, Austria; Mayo Clinic, Scottsdale, Arizona, USA; Department of Oncology, Prince of Wales Hospital, Randwick, New South Wales, Sydney, Australia; Celgene Corporation, Summit, New Jersey, USA; Department of Oncology, Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319641PMC
February 2015

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

J Natl Cancer Inst 2015 Feb 31;107(2). Epub 2015 Jan 31.

Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia (DG); Royal Victoria Regional Health Centre, Barrie, ON, Canada (RHEM); Hôpital Beaujon, Clichy, France (PH); Klinikum Grosshadern, University of Munich, Munich, Germany (VH); Universitätsklinikum Würzburg, Würzburg, Germany (VK); Hospital Clinico San Carlos, Madrid, Spain (JS); Medizinische Universität Wien, Wien, Austria (WS); Ospedale Niguarda Ca' Granda, Milan, Italy (SS); Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (JT); Hôpital Saint Antoine, Paris, France (LT); Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy (GT); Hôpital Erasme, Brussels, Belgium (JLVL); Royal Hobart Hospital, Hobart, Australia (RY); Celgene Corporation, Summit, NJ (DNP); Celgene Corporation, Summit, NJ (BL); Celgene Corporation, Boudry, Switzerland (AR); Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ (DDVH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju413DOI Listing
February 2015

Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.

Expert Rev Gastroenterol Hepatol 2014 Sep 31;8(7):739-47. Epub 2014 May 31.

Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474124.2014.925799DOI Listing
September 2014

Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.

Mol Cancer Ther 2014 Sep 22;13(9):2215-25. Epub 2014 Jul 22.

CanBas Co., Ltd., Numazu, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0808DOI Listing
September 2014

A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges.

PLoS One 2013 30;8(10):e76438. Epub 2013 Oct 30.

Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare (VGPCC), Scottsdale, Arizona, United States of America ; The Translational Genomics Research Institute, Phoenix, Arizona, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0076438PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813699PMC
August 2014

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.

Cancer Discov 2014 Aug 29;4(8):905-13. Epub 2014 May 29.

Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125497PMC
August 2014

Taxanes: impact on pancreatic cancer.

Anticancer Drugs 2014 May;25(5):584-92

aDepartment of Medicine, University of Washington, Seattle, Washington bTranslational Genomics Research Institute (TGen)/Virginia Piper Cancer Center, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000073DOI Listing
May 2014

Targeting the nucleolus for cancer-specific activation of p53.

Drug Discov Today 2014 Mar 28;19(3):259-65. Epub 2013 Aug 28.

The Translational Genomics Research Institute, 445 N. Fifth Street, Phoenix, AZ 85004, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2013.08.012DOI Listing
March 2014

Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.

J Proteome Res 2014 Feb 12;13(2):395-407. Epub 2013 Dec 12.

Complex Carbohydrate Research Center, ‡Chemistry Department, and §Department of Biochemistry and Molecular Biology, University of Georgia , Athens, Georgia 30602, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr400422gDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946306PMC
February 2014

A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors.

Clin Cancer Res 2014 Jan 4;20(2):445-55. Epub 2013 Oct 4.

Authors' Affiliations: Tufts University School of Medicine, Boston, Massachusetts; Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas; Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, New York; University of California San Diego; Biogen Indec, San Diego, California; University of Texas M.D. Anderson Cancer Center, Houston, Texas; and TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1257DOI Listing
January 2014

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

N Engl J Med 2013 Oct 16;369(18):1691-703. Epub 2013 Oct 16.

From the Translational Genomics Research Institute, Phoenix, and Virginia G. Piper Cancer Center, Scottsdale - both in Arizona (D.D.V.H., R.K.R.); Cancer Specialists, Fort Myers, FL (T.E.); Arena Oncology Associates, Lake Success (F.P.A.), and Roswell Park Cancer Institute, Buffalo (W.W.M.) - both in New York; University of Washington, Seattle (E.G.C.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (J. Infante); Princess Margaret Hospital, Toronto (M.M.); Atlanta Cancer Care (T.S.) and Georgia Cancer Specialists (M.N.S.) - both in Atlanta; Blokhin Cancer Research Center, Moscow (S.A.T.); Southern Health, East Bentleigh, VIC (M.H.), Prince of Wales Hospital, Sydney (D.G.), and Bionomics, Thebarton, SA (J. Iglesias) - all in Australia; San Raffaele Scientific Institute, Milan (M.R.); Tom Baker Cancer Centre, Calgary, AB, Canada (S.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (D.L.); University of Pittsburgh Medical Center, Pittsburgh (N.B.); Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona (J.T.); Centro Integral Oncológico Clara Campal, Madrid (M.H.); University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium (E.V.C.); and Celgene, Summit, NJ (X.W., M.F.R.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1304369
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1304369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631139PMC
October 2013

Isolation and characterization of muscle fatigue substance with anti-tumor activities.

J Cancer 2013 9;4(4):343-9. Epub 2013 May 9.

Division of Clinical Translational Research, Translational Genomics Research Institute, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.5418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654491PMC
May 2013